December 2 Biotech Update- Getting Ready for ASH

Last week ended well for biotechs and today was a little more of the same with perhaps some consolidation. News has been relatively limited as most traders/investors/general biotech followers are gearing up for ASH. I will be heading down on Friday and staying through Tuesday, which means there will not be any updates this Friday, […]

November 20-EOD (or midday)

In terms of the sector it is more of the same with an inline to slight outperformance of the market writ large (when the market is treading water or going moderately higher). Despite this positive action I always get worried when I see reports that newsletter writer bearish sentiment is at multi-decade lows (often viewed […]

November 19- EOD

The sector was doing fine yesterday until Icahn dumped on the market and everything got caught in the crossfire. This morning they are doing fine again, so it seems that as long as there is not a larger market selloff biotechs might just get time to catch their footing. Of course, it is still an […]

November 18-EOD

Thankfully there was not a lot of news but biotechs did not just drift lower. I still worry about tax loss selling hitting the sector (or at least the small to mid caps) heading into the end of the year but it is nice to see that the sector can tread water on no news […]

November 15-EOD

It has been a relatively quiet day in biotech land, which is fine as it has been a busy week. I saw more of the same with a mixed performance and stocks reacting to news specific to the company and those with little news were drifting. 1. I have been spending a lot of time […]

November 14- EOD

It is a similar market day as earlier this week with some definite movers to the upside and downside but with nothing that is general to the sector. If anything it is slightly weaker than the market at large but not in any dramatic sense. Sector seems more driven by stock specific stories rather than […]

November 13-EOD

It is difficult to get a real sense of where the sector is going outside of down. Obviously one could draw the conclusion that sentiment is negative (and it is) but I am seeing more pockets of strength than the other days. What is difficult is that there does not really seem to be a […]

November 12- EOD

Well, I think it was more of the same in the sector writ large with the biggest news obviously being SRPT, which I will touch on below. I was surprised to see the small caps hold up as well as they did on the news and that is a slight positive for the sector going […]

November 11- EOD

I am gone for a little while and the market goes crazy, bounces, and then we have today which has both sell offs and rallies. To be honest, it is difficult to get a good read on the sector sentiment writ large at this point and at those times it seems the best bet is […]

November 5- EOD

The morning looked bad but the sector came back a little. There was some sporadic buying of oncology names but nothing major. It will be very interesting to see how the sector responds to the ASH abstracts. Obviously there will be winners and losers but the question in my mind is how will the PPS […]

November 4- EOD

(This was from yesterday. Due to the server issues, I am not sure many of you saw it, so I am reposting.) I take one day to not write an EOD and biotechs sell off. Well, they have been weak for awhile so no real surprise but at least the selling does not seemed related […]

October 31- EOD

ARIA is doing its best to single handedly crush biotech sentiment and grind it into a bloody pulp. As I have said before, if this is the bursting of a real speculative bubble then we have another five to ten years of selling (I think it took tulip prices over a century to recover and […]

October 30- EOD

The sector seems almost perilously balanced between putting in a solid base for the next leg higher and setting up for another leg lower. The freefall that we have seen in recent weeks has slowed but volumes remain pathetic (especially in the small cap space), which means buyers are not quite interested. Of course, when […]